167 related articles for article (PubMed ID: 14753246)
1. The formulation and evaluation of a CFC-free budesonide pressurised metered dose inhaler.
Ganderton D; Lewis D; Davies R; Meakin B; Church T
Respir Med; 2003 Nov; 97 Suppl D():S4-9. PubMed ID: 14753246
[TBL] [Abstract][Full Text] [Related]
2. Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: a randomised controlled trial.
Escribano A; Tutuncu A; Löhr I; Carlholm M; Polanowski T
Curr Med Res Opin; 2006 Jun; 22(6):1085-92. PubMed ID: 16846541
[TBL] [Abstract][Full Text] [Related]
3. Budesonide administered using chlorofluorocarbon and hydrofluoroalkane pressurized metered-dose inhalers: pharmacokinetics, pharmacodynamics and clinical equivalence.
Singh D; Tutuncu A; Lohr I; Carlholm M; Polanowski T
Int J Clin Pharmacol Ther; 2007 Sep; 45(9):485-95. PubMed ID: 17907591
[TBL] [Abstract][Full Text] [Related]
4. Clinical equivalence of budesonide dry powder inhaler and pressurized metered dose inhaler.
Srichana T; Juthong S; Thawithong E; Supaiboonpipat S; Soorapan S
Clin Respir J; 2016 Jan; 10(1):74-82. PubMed ID: 25043636
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.
Hochrainer D; Hölz H; Kreher C; Scaffidi L; Spallek M; Wachtel H
J Aerosol Med; 2005; 18(3):273-82. PubMed ID: 16181002
[TBL] [Abstract][Full Text] [Related]
6. Plume temperature emitted from metered dose inhalers.
Brambilla G; Church T; Lewis D; Meakin B
Int J Pharm; 2011 Feb; 405(1-2):9-15. PubMed ID: 21129465
[TBL] [Abstract][Full Text] [Related]
7. Factors affecting the efficiency of aerosol therapy with pressurised metered-dose inhalers through plastic spacers.
Chuffart AA; Sennhauser FH; Wildhaber JH;
Swiss Med Wkly; 2001 Jan; 131(1-2):14-8. PubMed ID: 11205181
[TBL] [Abstract][Full Text] [Related]
8. Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers.
Ganderton D; Lewis D; Davies R; Meakin B; Brambilla G; Church T
Respir Med; 2002 Aug; 96 Suppl D():S3-8. PubMed ID: 12201079
[TBL] [Abstract][Full Text] [Related]
9. Modulite technology: pharmacodynamic and pharmacokinetic implications.
Woodcock A; Acerbi D; Poli G
Respir Med; 2002 Aug; 96 Suppl D():S9-15. PubMed ID: 12201080
[TBL] [Abstract][Full Text] [Related]
10. Developing an in vitro understanding of patient experience with hydrofluoroalkane-metered dose inhalers.
Doub WH; Shah V; Limb S; Guo C; Liu X; Ngo D
J Pharm Sci; 2014 Nov; 103(11):3648-3656. PubMed ID: 25228114
[TBL] [Abstract][Full Text] [Related]
11. Equivalent asthma control and systemic safety of inhaled budesonide delivered via HFA-134a or CFC propellant in a broad range of doses.
Grzelewska-Rzymowska I; Malolepszy J; de Molina M; Sladek K; Zarkovice J; Siergiejko Z;
Respir Med; 2003 Nov; 97 Suppl D():S10-9. PubMed ID: 14753247
[TBL] [Abstract][Full Text] [Related]
12. A pilot study to assess lung deposition of HFA-beclomethasone and CFC-beclomethasone from a pressurized metered dose inhaler with and without add-on spacers and using varying breathhold times.
Leach CL; Colice GL
J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23(6):355-61. PubMed ID: 20575669
[TBL] [Abstract][Full Text] [Related]
13. Moving from CFC aerosol to HFA aerosol or dry powder inhalers: what do patients think?
Hartung TK; Allbutt H; Dewar M; Innes JA; Crompton GK
Respiration; 2002; 69(4):314-9. PubMed ID: 12169743
[TBL] [Abstract][Full Text] [Related]
14. Principles of metered-dose inhaler design.
Newman SP
Respir Care; 2005 Sep; 50(9):1177-90. PubMed ID: 16122401
[TBL] [Abstract][Full Text] [Related]
15. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.
Houghton CM; Langley SJ; Singh SD; Holden J; Monici Preti AP; Acerbi D; Poli G; Woodcock A
Br J Clin Pharmacol; 2004 Oct; 58(4):359-66. PubMed ID: 15373928
[TBL] [Abstract][Full Text] [Related]
16. A study comparing the clinical pharmacokinetics, pharmacodynamics, and tolerability of triamcinolone acetonide HFA-134a metered-dose inhaler and budesonide dry-powder inhaler following inhalation administration.
Argenti D; Shah B; Heald D
J Clin Pharmacol; 2000 May; 40(5):516-26. PubMed ID: 10806605
[TBL] [Abstract][Full Text] [Related]
17. Development and performance of a new hydrofluoroalkane (HFA 134a)-based metered dose inhaler (MDI) of salmeterol.
Peyron ID; Britto IL; Benissan LB; Tardieu BZ
Respir Med; 2005 Apr; 99 Suppl A():S20-30. PubMed ID: 15777605
[TBL] [Abstract][Full Text] [Related]
18. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology.
Acerbi D; Brambilla G; Kottakis I
Pulm Pharmacol Ther; 2007; 20(3):290-303. PubMed ID: 16890465
[TBL] [Abstract][Full Text] [Related]
19. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects.
Nave R; Zech K; Bethke TD
Eur J Clin Pharmacol; 2005 May; 61(3):203-8. PubMed ID: 15824911
[TBL] [Abstract][Full Text] [Related]
20. The technical transition to CFC-free inhalers.
Tansey I
Br J Clin Pract Suppl; 1997 May; 89():22-7. PubMed ID: 9519509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
